SEC Filing Summary: Pieris Pharmaceuticals, Inc. (PIRS)
Business Context and Reporting Period
This Form 8-K was filed on January 17, 2020, by Pieris Pharmaceuticals, Inc., a Nevada corporation and emerging growth company. The filing serves as a current report to notify stockholders of the date for the 2020 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice regarding corporate governance and does not contain financial performance data.
Material Changes
The primary material change disclosed is the scheduling of the 2020 Annual Meeting for June 23, 2020. This date represents a shift of more than 30 days from the anniversary of the 2019 Annual Meeting, which was held on July 31, 2019. Consequently, the company is providing advance notice of the meeting date and proposal deadlines in accordance with Rule 14a-5(f) of the Exchange Act.
Guidance, Outlook, and Risks
The filing contains no management commentary on business outlook, financial guidance, risks, contingencies, or unusual items. The document is limited to the logistical details of the upcoming stockholder meeting.
Key Facts for Investors to Verify
- Meeting Date: The 2020 Annual Meeting is scheduled for June 23, 2020.
- Proposal Deadline (Proxy Statement): Stockholder proposals for inclusion in the proxy statement must be received by the close of business on February 22, 2020.
- Proposal Deadline (Meeting Floor): Stockholder proposals for presentation at the meeting must be received no earlier than February 24, 2020, and no later than March 25, 2020.
- Regulatory Basis: The notice is required due to the meeting date shifting more than 30 days from the prior year's anniversary.